Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Document first published:: 9 July 2020
Page updated:: 2 August 2021
Topic:: Commissioning, Medicine, Specialised commissioning
Publication type:: Policy or strategy

Infliximab will be available as a treatment option through routine commissioning for refractory or progressive neurosarcoidosis within the criteria set out in this document.

Document

$Clinical Commissioning Policy: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)$

Clinical Commissioning Policy: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

PDF
269 KB
10 pages

Document

$Clinical panel report June 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)$

Clinical panel report June 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

PDF
35 KB
3 pages

Document

$Clinical panel report February 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)$

Clinical panel report February 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

PDF
25 KB
1 pages

Document

$Consultation report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)$

Consultation report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

PDF
41 KB
3 pages

Document

$CPAG summary report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)$

CPAG summary report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

PDF
58 KB
6 pages

Document

$Evidence review: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)$

Evidence review: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

PDF
449 KB
39 pages

Document

$Stakeholder-engagement-report-refractory-or-progressive-neurosarcoidosis-(adults-and-post-pubescent-children)$

Stakeholder-engagement-report-refractory-or-progressive-neurosarcoidosis-(adults-and-post-pubescent-children)

PDF
39 KB
3 pages

Cookies on the NHS England and NHS Improvement website

Clinical Commissioning Policy: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical panel report June 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical panel report February 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Consultation report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

CPAG summary report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Evidence review: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Stakeholder-engagement-report-refractory-or-progressive-neurosarcoidosis-(adults-and-post-pubescent-children)